Trialect

Active

Rheumatology Fellowship United States

Pfizer Inc.

It is our intent to support adult and pediatric rheumatology fellowship programs for rheumatologists at institutions with clinical training programs that have a strong focus on clinical practice, research, and education to further the understanding of rheumatologic diseases (Rheumatoid Arthritis, Spondyloarthropathies, Idiopathic Inflammatory Myositis, Juvenile Idiopathic Arthritis, and Lupus).

The goal of this RFP is to offer salary support for adult and pediatric rheumatology fellowship programs. We aim to support new and established fellowship programs that have a robust clinical and research program. Grants will be awarded based on the strength of the requesting organization’s ability to provide expert mentorship, training, and guidance to the fellow.

Application submission deadline: September 24, 2024

Specialties

Curriculum Development

Medical - Clinical Science

Medical

Eligibility Requirements

Geographic Scope • United States

• Accredited, US-based academic institution. • Do not include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual. • Institutions with fellowship programs that include independent research and a strong mentoring program. Clinical training must be included in the program. • Examples of independent research may include: observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; use of screening tools and their impact on improvement of patient health. • Examples of research that would not be eligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, in-vitro, etc.). • Examples of clinical training include: educational time with an interdisciplinary team in review of case examples and relevant didactic training as well as use of tools for improvement in patient health for rheumatological conditions. • Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care. • No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset.